+88.6%
TGT vs MRNA
+945.0%
-856.4%
-12.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.6% | +13.1% | -7.5% | +5.4% |
| 7D | +9.5% | +20.6% | -11.2% | +9.1% |
| 30D | +6.6% | +27.1% | -20.5% | +6.0% |
| 3M | +11.0% | +353.4% | -342.4% | +6.6% |
| 6M | +29.9% | +446.3% | -416.4% | +24.0% |
| YTD | +71.4% | +776.2% | -704.7% | +55.1% |
| 1Y | +88.6% | +987.9% | -899.3% | +60.7% |
| All | +88.6% | +945.0% | -856.4% | +60.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling